KPV

Mechanism of Action

KPV is the C-terminal tripeptide (Lys-Pro-Val) of alpha-melanocyte-stimulating hormone (α-MSH) that exerts anti-inflammatory effects primarily by inhibiting NF-κB and MAP kinase signaling pathways in both immune and epithelial cells. Unlike full-length α-MSH, KPV does not appear to work through classical melanocortin receptor signaling or cAMP elevation, but instead inhibits IL-1β functions and reduces pro-inflammatory cytokine production through alternative mechanisms that may involve direct intracellular action following cellular uptake via the PepT1 transporter. Key Pathways: NF-κB inhibition (reduces nuclear translocation and transcriptional activity), MAP kinase pathway suppression, PepT1-mediated cellular uptake into epithelial and immune cells, IL-1β functional inhibition, Pro-inflammatory cytokine downregulation (TNF-α, IL-1β) The NF-κB and MAP kinase inhibition translates to reduced inflammatory cytokine production, which in animal models of colitis leads to decreased tissue damage, reduced inflammatory cell infiltration, and faster recovery from intestinal inflammation. For skin conditions, these same anti-inflammatory pathways would theoretically reduce the inflammatory cascades underlying eczema, psoriasis, and acne, while KPV's demonstrated wound healing effects in corneal tissue suggest potential benefits for skin repair.

Common Dose Reference Ranges

Educational reference ranges only — discuss actual dosing with a qualified healthcare provider.

Full KPV protocols — frequency, timing, cycle length, reconstitution & research